Hatchtech Pty Ltd   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Melbourne Australia (2001)
Status: Left NME R&D (2015)

Organization Overview

First Clinical Trial
2011
NCT01336647
First Marketed Drug
2020
abametapir (Xeglyze)
First NDA Approval
2020
abametapir (Xeglyze)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

HATCHTECH

Active Ingredients

Marketed Drugs (1)

abametapir (Xeglyze) (2020 NDA)

Drugs in Phase 3 Trials (1)

abametapir (Xeglyze) (9 trials)

Drugs in Phase 1 Trials (3)

moxifloxacin (avelox) (1 trial)

sodium chloride (2 trials)

sodium monododecyl sulfate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lice Infestations (Phase 3)

Mite Infestations (Phase 3)

Parasitic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 4